Attract talent




Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.


Add photos to showcase Immunovant’s culture


Add Immunovant’s values

Insider experiences

Share your experience of working at Immunovant

Peter Salzmann
Chief Executive Officer
Renee Barnett
Chief Financial Officer
William Macias
Chief Medical Officer
Julia G. Butchko
Chief Development & Technology Officer
Mark Levine
Chief Legal Officer & Corporate Secretary
Ronald Bates
VP, CMC Process Development
Yan Zheng
VP of Biostatistics & Programming
Jody Roth
VP of Global Regulatory Affairs
Lauren Schrier
VP, Marketing
Lesa Valentine
VP, Quality
Joanne Sloan Lancaster
VP, Program & Alliance Management

Add your teams to show how people work together at Immunovant

Add jobs to your org chart to show candidates who they’ll work with

Publish company announcements to get more exposure

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.